PBD Vivoryon Therapeutics AG

Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million

Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.



Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million



To access the press release, please click .









EN
26/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vivoryon Therapeutics AG

 PRESS RELEASE

Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Busin...

Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment effect, further supporting plans to advance development in stage 3b/4 DKD Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster session at ASN kidney week, the world’s premier nephrology meeting Successful completion of private placement supported by ex...

 PRESS RELEASE

Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Ope...

Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 Halle (Saale) / Munich, Germany, November 25, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its third quarter financial results for the period ended September 3...

 PRESS RELEASE

Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomar...

Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meetingVIVIAD analyses continue to support varoglutamstat’s potential in kidney disease, and consistently provide further evidence for a beneficial impact on kidney function based on...

 PRESS RELEASE

Vivoryon Therapeutics N.V. to Present at Upcoming Conferences

Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Halle (Saale) / Munich, Germany, November 3, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November: American Society of Nephrology (ASN) Kidney Week 2025Date: November 5 –...

 PRESS RELEASE

Vivoryon Therapeutics N.V. Successfully Completes Private Placement Ra...

Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTIO...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch